The Hidden Profit Engine of the Medical Equipment Industry
The scanner wins the tender. The cartridges, service contracts and software licences that follow it earn the money, often for a decade. Here is how recurring revenue works in medical equipment, and what it means in India.
Summary
- In medical equipment, the machine is usually the lower-margin part of the relationship; consumables, service contracts and software earn steadier and higher margins for years after installation.
- The filings show it: services were about 34% of GE HealthCare's revenue in Q2 2024, and recurring revenue was about 80% of Outset Medical's Q4 2024 revenue.
- For Indian device makers the lesson is to design the consumable and service model with the product; for hospital CFOs it is to negotiate lifetime cost, not purchase price.
The medical equipment industry sells itself through its machines: the MRI in the brochure, the surgical robot at the conference, the new CT system in the press release. They win innovation awards and hospital tenders.
They are not where most of the durable profit sits. That comes afterwards, from the reagents an analyser consumes, the cartridge used in every dialysis session, the service contract that keeps a scanner running, and the software licence renewed every year.
How big the aftermarket is
Research firms size the pieces differently, which is a warning to treat any single headline number with care. MarketsandMarkets valued the global medical equipment maintenance market at $54 billion in 2024 and projects $88.9 billion by 2029. Consumables and disposables are larger again, though published estimates for them are inconsistent enough that we would not quote one as fact.
The direction is not in doubt. For a manufacturer with a large installed base, what it sells after installation can equal or exceed what it earns on new equipment, and it arrives whether or not hospitals are buying new machines this year.
Razor and blade, with a clinical twist
The logic is the old razor-and-blade model: price the hardware keenly, sometimes close to cost, and earn a steady, higher margin on what it needs to keep running. Medical equipment runs this playbook with unusual precision because the consumables are often proprietary and clinically validated only with that machine.
- Diagnostics. A laboratory analyser or PCR platform earns on the reagents and test kits it consumes, every day, for its whole life.
- Dialysis. A haemodialysis system runs on single-use cartridges bought from the manufacturer for each treatment.
- Glucose monitoring. A continuous glucose monitor's sensors are replaced every 10 to 14 days, which turns one patient into a subscription. Our piece on wearable medical devices covers that market.
- Imaging. A CT or MRI system brings service contracts, software licences and upgrades that can run to a large share of the original price over its life.
Outset Medical, maker of the Tablo dialysis system, shows how far the model can go. In the fourth quarter of 2024 its recurring revenue from cartridges and service was $23.7 million, up 17% on the year and about 80% of total revenue for the quarter. Every console placed in a hospital turns each later treatment into a sale.
The machine opens the account. The account pays for a decade.
How the large companies do it
Recurring revenue as a share of total at selected device makers
| Company | Period | Recurring or service revenue | Share of total |
|---|---|---|---|
| GE HealthCare | Q2 2024 | Services $1,632m of $4,839m | about 34% |
| Outset Medical | Q4 2024 | Recurring $23.7m of $29.5m | about 80% |
| Outset Medical | FY 2024 | Consumables and services $83.9m of $113.7m | about 74% |
| 908 Devices | FY 2024 | Recurring revenue, up 42% on the year | 39% |
GE HealthCare, a business of about $19.7 billion in 2024 revenue, earned roughly a third of its quarterly revenue from services and sells multi-year service agreements as a way for hospitals to guarantee uptime. Siemens Healthineers, with more than €22 billion of revenue in fiscal 2024, builds its imaging and diagnostics franchise on long-term service contracts, remote monitoring and software. Medtronic's portfolio in cardiovascular, diabetes and surgery carries a large consumable tail on every implant and device placed.
Research firms estimate that original manufacturers hold roughly 43% of equipment service revenue worldwide. They defend it with proprietary diagnostic software, certified engineers and control of genuine spare parts.
The three streams
- Consumables and disposables. Reagents, cartridges, sensors, single-use instruments. Diagnostics platforms are the purest example, since the reagent revenue rises with every test run.
- Service and maintenance. Comprehensive and annual maintenance contracts, priced higher for faster response. Hospitals pay for certainty because an idle scanner costs them far more than the contract.
- Software and digital services. Analytics, remote monitoring and AI tools sold as annual licences or subscriptions. This is the fastest-growing stream and the most predictable once installed; our piece on AI in medical devices looks at what those tools actually do.
Why investors pay more for it
Recurring revenue is steadier: patients keep coming whatever the economy does, so consumables and service keep selling. It usually carries better margins; an industry rule of thumb puts capital equipment gross margins around 40% to 55% and mature consumable and service lines at 60% to 70% or more, though company disclosures rarely split it that cleanly. It is sticky, because changing a service provider or consumable risks downtime, compliance gaps and retraining. And it earns a higher valuation multiple. A device company with most of its revenue from its installed base is valued very differently from one that must win every sale afresh.
The installed base is therefore the asset that matters. 908 Devices, a maker of handheld mass spectrometers, grew its installed base 23% to 3,504 units in 2024, and recurring revenue rose to 39% of the total. Placement deals, where a hospital gets equipment on easy terms in return for a long consumables commitment, are now standard in diagnostics and dialysis for exactly this reason.
Where the model is under pressure
- Independent service organisations undercut OEM service pricing, and hospitals increasingly use them for older equipment.
- Buyer power. Large hospital groups and purchasing consortia negotiate consumable prices down year after year.
- Regulation and reimbursement. A change in how a test or procedure is paid for can shrink a consumable franchise quickly.
- Waste. Single-use products are under growing environmental scrutiny, even where infection control makes the clinical case for them.
What this means in India
For Indian device makers, including those building in the new clusters at AMTZ and Hyderabad, the lesson is to design the consumable, service and software model with the product rather than after it. A device sold once at a thin margin into a price-sensitive market rarely builds a business. A device that brings a service contract and a consumable stream with it can, and it is what investors in medtech will look for.
For hospital CFOs, the same logic runs in reverse. The purchase price is often the smaller part of what a machine will cost. Before signing, model the lifetime cost: consumables at expected volumes, the maintenance contract after warranty, software licences and upgrades, and the price of downtime. Negotiate those terms at purchase, when your bargaining position is strongest, and track them afterwards as a line in the hospital's revenue and cost system.
How useful was this article?
One tap. It tells us what to write more of.
About the author
SRF Capital Studio
The next one
Get what we publish next, by email.
Working notes on raising, borrowing, protecting, growing and structuring capital in India. One email a week at most, and you can leave any time.
We use your address only to send this. See our privacy policy.
We store your address to send you these emails and nothing else. See our privacy policy.
Related reading
